Interestingly, it has been reported that mCRC patients with right-sided lesions, who normally present with worse disease outcomes compared to those with left-sided tumours, have shown improved responses to combined FOLFOXIRI and bevacizumab treatment irrespective of BRAF and RAS mutational status [98]. The gene discussed is BRAF; the disease is neoplasm.